跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
MINT-GABAPENTIN - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
MINT-GABAPENTIN
Authorized
STANDARD
MINT-GABAPENTIN
mint pharmaceuticals inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
35b6df633e966359
Company
mint pharmaceuticals inc
Type
Standard
Approval Details
Approval Id
35b6df633e966359
Drug Approval Canada Name
MINT-GABAPENTIN
Product Name
MINT-GABAPENTIN
Status
Marketed
Status Date
2023-08-25
Original Market Date
2023-08-25
Din
02408899
Drug Class
Human
Dosage Form
Capsule
Route Of Administration
Oral
Schedule
Prescription
Ahfs
28:12.92
Atc Original
N02BF01 GABAPENTIN
Atc Name
n 02 bf 01
Aig Number
0125929003
Company Name
mint pharmaceuticals inc
Company Address
6575 Davand Drive, Mississauga, Ontario, Canada, L5T 2M3
Active Ingredients
GABAPENTIN
300 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
35b6df633e966359
Type
Standard
Back to Health Canada Approvals